31550B35-DA39-4294-8368-811A412B2E3A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.6938239159001314
- age_years
- 50
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.550
- INTERFERON_ALPHA_RESPONSE+0.546
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.523
- INTERFERON_GAMMA_RESPONSE+0.487
- DNA_REPAIR+0.447
- MYC_TARGETS_V1+0.417
- ALLOGRAFT_REJECTION+0.415
- TNFA_SIGNALING_VIA_NFKB+0.414
- UV_RESPONSE_UP+0.412
- ADIPOGENESIS+0.388
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.416
- MITOTIC_SPINDLE-0.371
- WNT_BETA_CATENIN_SIGNALING-0.327
- UV_RESPONSE_DN-0.295
- SPERMATOGENESIS-0.232
- ANDROGEN_RESPONSE-0.229
- KRAS_SIGNALING_DN-0.193
- ESTROGEN_RESPONSE_EARLY-0.174
- APICAL_JUNCTION-0.121
- APICAL_SURFACE-0.083
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.928 |
| 2 | FBB4DAFD-11F1-498F-95C5-73D8B735465B | — | — | 0.927 |
| 3 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.918 |
| 4 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.918 |
| 5 | DB8DD33B-34B6-4F4B-AD87-D666899A26BC | — | — | 0.916 |
| 6 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.915 |
| 7 | 4B4647B5-1964-49A9-AC25-89AB4A669341 | — | — | 0.915 |
| 8 | 9E5B5D00-45A2-48A9-9F57-0B4AAE9E4E25 | — | — | 0.902 |
| 9 | B8AED170-C88C-4A86-8377-93B5D14AB334 | — | — | 0.894 |
| 10 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.550 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.546 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.523 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.487 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.447 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.417 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.415 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.414 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.412 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.388 | Inavolisib | — uncovered |
| APOPTOSIS | 0.387 | Idelalisib | — uncovered |
| COAGULATION | 0.378 | Binimetinib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.355 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.348 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.333 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.309 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.288 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.275 | Inavolisib | — uncovered |